Follow The Filings

ALDX Aldeyra Therapeutics Inc.

Health Care, filed as ALDEYRA THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.1%
  • $332K

Who owns this now

Largest portfolio weights among holders, up to 0.1% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors 0.05%

Who owns ALDX

Sorted by value, long equity only, as of 2026 Q2.

History
Palo Alto Investors 0.05% Hold 155,709 $332K History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ALDX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ALDX insider trades
  • $524K bought by 3 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Todd C Brady CEO
    Buy
    $418K 250,000 shares at $1.67 +17% to stake
    Traded Jun 3 Filed Jun 5
    ↗
  2. Richard Douglas Director
    Buy
    $98K 70,000 shares at $1.40 +56% to stake
    Traded Mar 19 Filed Mar 20
    ↗
  3. Michael Alfieri Principal Financial Officer
    Buy
    $7,100 5,000 shares at $1.42 +200% to stake
    Traded Mar 18 Filed Mar 19
    ↗

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 1.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01 Filing Doc
8-K 5.02,5.07,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 7.01,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 5.02 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 9.01 Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$37.54M -$55.85M -$33.85M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $147.81M $104.07M $71.78M
Total non-current assets * $516,578 $534,216 $275,861
Total assets $148.33M $104.61M $72.06M
Total current liabilities $22.26M $18.6M $27.81M
Total non-current liabilities * $6.27M $15M $0M
Total equity $119.8M $71M $44.25M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$30.33M -$43.21M -$33.35M
Cash from investing $30M -$44.92M $47.74M
Cash from financing -$1.27M -$0.171M $1.12M
Net change in cash -$1.6M -$88.3M $15.51M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.